logo
Share SHARE
FONT-SIZE Plus   Neg

Vanda Pharma Acquires Rights To NK-1 Receptor Antagonist From Eli Lilly

Vanda Pharmaceuticals Inc. (VNDA) said it has acquired an exclusive world-wide license from Eli Lilly and Co. (LLY) to develop and commercialize a small molecule neurokinin 1 receptor, or NK-1R, antagonist for all human indications.

As per the terms of the agreement with Eli Lilly, Vanda Pharma will pay an initial license fee of $1 million and will be responsible for all development costs. Eli Lilly is also eligible to get extra payments on the basis of achievement of specified development and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. These milestones include $4 million for pre-NDA approval milestones and up to $95 million for future regulatory approval and sales milestones.

Vanda Pharma stated that in 2012, it plans to initiate and complete the technology transfer activities and further examine the clinical and commercial profile of VLY-686. This strategic evaluation will further inform potential indications for an early development clinical program, noted the company.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Mastercard Inc. said that after April 2018, customers will no longer be required to sign for any purchases they made on the card at retail. The company added that the change, which will apply to both credit and debit cards, will not have any negative impact on safety. Procter & Gamble Company (PG) Friday reported a profit for the first quarter fiscal year 2018 that grew 5 percent from last year, while quarterly net sales increased one percent. Adjusted earnings per share topped analysts' expectations. The company maintained its expectation for fiscal year 2018. Conglomerate General Electric Co. reported Friday weak earnings in its third quarter, despite increased revenues and orders. Adjusted earnings were sharply lower than market estimates, while top line beat their view. In pre-market activity, GE shares were losing around 5 percent.
comments powered by Disqus
Follow RTT